X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (16) 16
female (13) 13
aged (12) 12
cancer (12) 12
male (12) 12
middle aged (12) 12
oncology (10) 10
pathology (10) 10
adult (8) 8
aged, 80 and over (8) 8
prognosis (8) 8
life sciences (7) 7
immunohistochemistry (6) 6
tumors (6) 6
analysis (5) 5
gene expression (5) 5
retrospective studies (5) 5
treatment outcome (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biomarkers, tumor - metabolism (4) 4
biopsy (4) 4
carcinoma (4) 4
colorectal cancer (4) 4
disease-free survival (4) 4
expression (4) 4
medical prognosis (4) 4
neoplasm staging (4) 4
research (4) 4
biomarkers (3) 3
bladder cancer (3) 3
breast cancer (3) 3
care and treatment (3) 3
clinical neurology (3) 3
colon-cancer (3) 3
colorectal neoplasms - drug therapy (3) 3
colorectal neoplasms - mortality (3) 3
colorectal neoplasms - pathology (3) 3
diagnosis (3) 3
france (3) 3
genetic aspects (3) 3
health aspects (3) 3
human papillomavirus (3) 3
kaplan-meier estimate (3) 3
mutation (3) 3
neurosciences (3) 3
polymerase chain reaction (3) 3
prospective studies (3) 3
research article (3) 3
studies (3) 3
surgery (3) 3
survival (3) 3
1st-line treatment (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
accreditation (2) 2
activation (2) 2
adolescent (2) 2
angiogenesis (2) 2
angiopoietin-2 (2) 2
angiopoietin-2 - blood (2) 2
antibodies (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
authorization (2) 2
autophagy (2) 2
bevacizumab (2) 2
biomarkers, tumor - genetics (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cancer research (2) 2
cancer therapies (2) 2
capecitabine (2) 2
cell line, tumor (2) 2
cell lung-cancer (2) 2
cells (2) 2
cervical intraepithelial neoplasia (2) 2
cetuximab (2) 2
chemotherapy (2) 2
child (2) 2
child, preschool (2) 2
childhood (2) 2
cohort studies (2) 2
colorectal neoplasms - blood (2) 2
combined modality therapy (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
development and progression (2) 2
disease (2) 2
egfr (2) 2
epidemiology (2) 2
fluorouracil - administration & dosage (2) 2
fluorouracil - analogs & derivatives (2) 2
follow-up studies (2) 2
gastroenterology (2) 2
gastroenterology & hepatology (2) 2
gastroenterology and hepatology (2) 2
gene (2) 2
gene expression regulation, neoplastic (2) 2
genetics (2) 2
genotype (2) 2
growth-factor receptor (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Pathology, ISSN 0046-8177, 2013, Volume 44, Issue 6, pp. 992 - 1002
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 08/2014, Volume 14, Issue 1, pp. 143 - 143
Journal Article
Brain Pathology, ISSN 1015-6305, 07/2018, Volume 28, Issue 4, pp. 466 - 474
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 09/2012, Volume 36, Issue 9, pp. 1302 - 1316
Journal Article
Journal Article
Applied Immunohistochemistry & Molecular Morphology, ISSN 1541-2016, 08/2019, Volume 27, Issue 7, pp. e65 - e70
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2015, Volume 15, Issue 1, pp. 729 - 729
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 12/2013, Volume 13, Issue 1, pp. 611 - 611
Journal Article
Journal of Clinical Pathology, ISSN 0021-9746, 10/2010, Volume 63, Issue 10, pp. 873 - 878
Journal Article
Journal Article
CELLS, ISSN 2073-4409, 12/2018, Volume 7, Issue 12, p. 248
Early detection and targeted treatments have led to a significant decrease in mortality linked to breast cancer (BC), however, important issues need to be... 
SURVIVAL | autophagy | RECYCLING ENDOSOMES | CRISPR/Cas9 | shRNA | MEMBRANE | ATG9A | MDA-MB-436 | TRAFFICKING | triple negative breast cancer | EXPRESSION | CELL BIOLOGY
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2013, Volume 12, Issue 1, pp. 28 - 36
Micro-Abstract Half of patients with KRAS wild-type colorectal cancer do not benefit from adding anti–epithelial growth factor receptor (EGFR) to standard... 
Hematology, Oncology and Palliative Medicine | Gastroenterology and Hepatology | Signal transducer and activator of transcription 3 (STAT3) | KRAS | Cetuximab | EGFR | Colorectal cancer | 1ST-LINE TREATMENT | ACTIVATION | CELL-CYCLE PROGRESSION | PHASE-III TRIAL | MUTATION STATUS | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | CETUXIMAB PLUS IRINOTECAN | NON-HODGKINS-LYMPHOMA | TRANSCRIPTION FACTOR | SIGNAL TRANSDUCER | ras Proteins - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Liver Neoplasms - mortality | Immunoenzyme Techniques | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Liver Neoplasms - secondary | Colorectal Neoplasms - metabolism | STAT3 Transcription Factor - metabolism | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Signal Transduction | Liver Neoplasms - drug therapy | Proto-Oncogene Proteins - genetics | Survival Rate | Mutation - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Liver Neoplasms - metabolism | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Colorectal Neoplasms - pathology | Index Medicus
Journal Article